Relay Therapeutics (RLAY) Interest & Investment Income (2019 - 2026)

Relay Therapeutics (RLAY) has reported Interest & Investment Income for 8 consecutive years, with -$172000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Interest & Investment Income fell 102.2% year-over-year to -$172000.0; the TTM figure through Mar 2026 stood at $38.9 million (down 31.38% YoY), while the FY2025 annual figure was $27.0 million, down 22.19% from the prior year.
• Interest & Investment Income slipped to -$172000.0 in Q1 2026 per RLAY's latest filing, from $25.6 million in the prior quarter.
• Across five years, Interest & Investment Income topped out at $32.0 million in Q4 2024 and bottomed at -$8.1 million in Q1 2022.
• Historically, Interest & Investment Income has averaged $6.7 million across 5 years, with a median of $6.4 million in 2025.
• Annual changes were most pronounced in 2022 — Interest & Investment Income sank 3697.35% — and 2024, when it soared 3163.44%.
• Relay Therapeutics' Interest & Investment Income stood at $5.4 million in 2022, then sank by 40.62% to $3.2 million in 2023, then soared by 904.42% to $32.0 million in 2024, then slipped by 20.26% to $25.6 million in 2025, then slumped by 100.67% to -$172000.0 in 2026.
• Business Quant data shows RLAY's Interest & Investment Income at -$172000.0 in Q1 2026, $25.6 million in Q4 2025, and $6.4 million in Q3 2025.